Final analysis of a nordic lymphoma group phase ib/iia trial of pixantrone, etoposide, bendamustine and, in cd20-positive tumors, rituximab in relapsed aggressive b- or t-cell lymphomas

Authors :: Peter Meyer
Helle Toldbod
Pieternella J. Lugtenburg
S. Mannisto
Judit Jørgensen
Sirpa Leppä
Harald Holte
Thomas Relander
Giorgio Minotti
Suvi-Katri Leivonen
Knut Liestøl
Francesco d'Amore
Grete F. Lauritzsen
Thomas Stauffer Larsen
Peter de Nully Brown
Unn-Merete Fagerli
P Menna
Source :: d'Amore, F, Leppä, S, Relander, T, Larsen, T S, Brown, P, Jørgensen, J, Mannisto, S, Lugtenburg, P, Leivonen, S-K, Holte, H, Fagerli, U M, Lauritzsen, G F, Meyer, P, Minotti, G, Menna, P, Liestøl, K & Toldbod, H 2021, ' Final analysis of a nordic lymphoma group phase ib/iia trial of pixantrone, etoposide, bendamustine and, in cd20-positive tumors, rituximab in relapsed aggressive b-or t-cell lymphomas ', Hematological Oncology, vol. 39, no. Suppl. 2 . https://doi.org/10.1002/hon.151_2880
Publication Year :: 2021

Language :: English
Database :: OpenAIRE
Journal :: d'Amore, F, Leppä, S, Relander, T, Larsen, T S, Brown, P, Jørgensen, J, Mannisto, S, Lugtenburg, P, Leivonen, S-K, Holte, H, Fagerli, U M, Lauritzsen, G F, Meyer, P, Minotti, G, Menna, P, Liestøl, K & Toldbod, H 2021, ' Final analysis of a nordic lymphoma group phase ib/iia trial of pixantrone, etoposide, bendamustine and, in cd20-positive tumors, rituximab in relapsed aggressive b-or t-cell lymphomas ', Hematological Oncology, vol. 39, no. Suppl. 2 . https://doi.org/10.1002/hon.151_2880
Accession number :: edsair.doi.dedup.....da5b31b56c942d5ffecf5d8cd51edbad
Full Text :: https://doi.org/10.1002/hon.151_2880

Full Text Access

Tools